Human Papilloma Virus Testing Market

Human Papilloma Virus Testing Market by Types (High-risk Human Papilloma Virus and Low-risk Human Papilloma Virus), Applications (Monoclonal & Polyclonal Antibodies, Immunoassays, Chromosome Analysis, Microarrays, Molecular Diagnostics, Flow Cytometry, Artificial Intelligence, Biosensors, and Microcomputers), End-users (Hospital & Clinics, Point of Care, and Diagnostic Centers), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-2007
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 31
  • No. Of Pages: 183
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global human papilloma virus testing market size is estimated to register a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing cases of cervical cancer world-wide.

Human Papilloma Virus Testing Market key takeaways

The human papillomavirus (HPV) test helps to identify human papillomavirus present in the cells, which can further develop the abnormal cervical cells or cervical cancer, and genital warts. Routine usage of the HPV test under the age of 30 years is not recommended by specialists, as it is not very helpful. HPV is a type of infection majorly occurred through sexually transmitted and very common in young people. However, HPV infections usually get easily recovered by itself within a year or two. As per a World Health Organization report, cervical cancer is the fourth most common cancer among women. The report stated that the number of the disease cases were around 570,000 in 2018, representing 6.6% of all female cancers and the mortality rate is 90% caused by cervical cancer in underdeveloped countries.

With the increasing cases of COVID-19 all over the world in 2020, patients’ visit for numerous elective medical procedures such as cancer screening and monitoring were found subsided. One key reason for the decreasing in cancer screening adoption was due to urgent shift of pharmaceutical companies to prioritize more on essential requirements and tackle the COVID-19 pandemic.

Market Trends, Drivers, Restraints, and Opportunities

  • High mortality rate due to HPV infection and rising cases especially in developing countries are key factors that are anticipated to boost the growth of the market in the coming years.
  • Shortcoming of primary screening tests such as false or negative outcome, and less sensitivity for the detection of the virus is expected to upsurge the market.
  • Increasing burden of cervical cancer globally which is more commonly found in females is another factor that fuel the market growth during the forecast period.
  • Constantly changing in rules & regulations related to cervical cancer screening and HPV vaccination are major obstacles affecting the growth of the HPV testing market.
  • Less-skilled healthcare workers operating the diagnostic devices is one of the primary reasons that can hamper the market growth.
  • Growing awareness regarding the link between HPV and cervical cancer along with the increasing demand for accurate diagnostic testing is also projected to grow the market substantially.

Scope of the Report

The report on the global human papilloma virus testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Human Papilloma Virus Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Types (High-risk Human Papilloma Virus and Low-risk Human Papilloma Virus), Applications (Monoclonal & Polyclonal Antibodies, Immunoassays, Chromosome Analysis, Microarrays, Molecular Diagnostics, Flow Cytometry, Artificial Intelligence, Biosensors, and Microcomputers), and End-users (Hospital & Clinics, Point of Care, and Diagnostic Centers)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Biomedical Diagnostics; Abbott; bioMerieux; CeMines, Inc; CanAG Diagnostics; Siemens Healthcare; Bio-Rad; Epigenomics; Fujirebio; Guided Therapeutics Inc; Ipsogen; Gen-Probe; J&J Diagnostics; Hologic; Polartechnics; Qiagen; Roche; Radient Pharmaceuticals; OncoLab; Sequenom; and Targeted Diagnostics & Therapeutics, Inc;  

Market Segment Insights

High-risk human papilloma virus segment is anticipated to hold a key market share

On the basis of types, the global human papillomavirus market is divided into high-risk human papilloma virus and low-risk human papilloma virus. The high-risk human papilloma virus segment is anticipated to hold a key market share during the forecast period owing to wide prevalence of high-risk disorders and availability of advanced diagnostic techniques for detecting the disorder.

Molecular diagnostic segment is expected to grow at a rapid pace

Based on applications, the market is segmented into monoclonal & polyclonal antibodies, immunoassays, chromosome analysis, microarrays, molecular diagnostics, flow cytometry, artificial intelligence, biosensors, and microcomputers. The molecular diagnostic segment is expected to grow at a rapid pace during the forecast period owing to the wide adoption of the diagnostic test for the detection of various types of high-risk HPV. Molecular diagnostic tests are helpful for finding out the most appropriate diagnosis and treatments for patients. Others factors such as signal amplification, probe amplification, and target amplification in the detection and screening of HPV are expected to upsurge the market share of the segment.

Human Papilloma Virus Testing Market by applications

Hospitals & clinics segment to register robust growth

On the basis of end-users, the global human papillomavirus market is segregated as hospital & clinics, point of care (PoC), and diagnostic centers. The hospitals & clinics segment is projected to register robust growth in the market during the forecast period as hospitals & clinics are well equipped with advanced diagnostic instruments, along with a wide availability of highly qualified medical personnel such as doctors, nurses, and technicians. However, the PoC segment is anticipated to exhibit an impressive growth rate in the coming years due to increased demand for self-treatment and faster introduction of advanced home settings to enable simple access of patients.

North America is anticipated to constitute a key market share

In terms of regions, the global human papillomavirus testing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key share of the market during the forecast period. The major factors attributing to the higher share market of the region are increasing cases of cancer and the initial stage of diagnosis and treatment awareness programs conducted by governments in the region. In addition to, governments led investments & grants have also positive impact on the growth of the HPV testing market in North America.

Meanwhile, the market of Asia Pacific is expected to grow at an impressive rate during the forecast period due to the rising prevalence of cervical cancer and sexually transmitted diseases such as HSV, and HIV, and cancroid. Advanced technology in screening assays, for determination of actual disease rather than the risk of predisposition to disease, are also projected to boost regional growth of market.

Human Papilloma Virus Testing Market by Regions

Segments

The global human papillomavirus testing market has been segmented on the basis of

Types

  • High-risk Human Papilloma Virus
  • Low-risk Human Papilloma Virus

Applications

  • Monoclonal & Polyclonal Antibodies
  • Immunoassays
  • Chromosome Analysis
  • Microarrays
  • Molecular Diagnostics
  • Flow Cytometry
  • Artificial Intelligence
  • Biosensors
  • Microcomputers

End-users

  • Hospital & Clinics
  • Point of Care
  • Diagnostic Centers

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Biomedical Diagnostics
  • Abbott
  • bioMerieux
  • CeMines, Inc.
  • CanAG Diagnostics
  • Siemens Healthcare
  • Bio-Rad
  • Epigenomics
  • Fujirebio
  • Guided Therapeutics Inc.
  • Ipsogen
  • Gen-Probe
  • J&J Diagnostics
  • Hologic
  • Polartechnics
  • Qiagen
  • Roche
  • Radient Pharmaceuticals
  • OncoLab
  • Sequenom
  • Targeted Diagnostics & Therapeutics, Inc.

Competitive Landscape

Some of the major players competing in the market are Biomedical Diagnostics; Abbott; bioMerieux; CeMines, Inc; CanAG Diagnostics; Siemens Healthcare; Bio-Rad; Epigenomics; Fujirebio; Guided Therapeutics Inc; Ipsogen; Gen-Probe; J&J Diagnostics; Hologic; Polartechnics; Qiagen; Roche; Radient Pharmaceuticals; OncoLab; Sequenom; and Targeted Diagnostics & Therapeutics, Inc.

These key players are mainly focusing on organic & inorganic strategies such as merger & acquisition, approvals for products and licenses, agreements, partnerships, collaborations, and regional expansions to sustain their revenue share in the market.

Human Papilloma Virus Testing Market by key players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Human Papilloma Virus Testing Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Human Papilloma Virus Testing Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Human Papilloma Virus Testing Market - Supply Chain
  4.5. Global Human Papilloma Virus Testing Market Forecast
     4.5.1. Human Papilloma Virus Testing Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Human Papilloma Virus Testing Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Human Papilloma Virus Testing Market Absolute $ Opportunity
5. Global Human Papilloma Virus Testing Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Human Papilloma Virus Testing Market Size and Volume Forecast by Types
     5.3.1. High-risk Human Papilloma Virus
     5.3.2. Low-risk Human Papilloma Virus
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Human Papilloma Virus Testing Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
     6.3.1. Monoclonal & Polyclonal Antibodies
     6.3.2. Immunoassays
     6.3.3. Chromosome Analysis
     6.3.4. Microarrays
     6.3.5. Molecular Diagnostics
     6.3.6. Flow Cytometry
     6.3.7. Artificial Intelligence
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Human Papilloma Virus Testing Market Analysis and Forecast by End Users
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by End Users
     7.2.2. Y-o-Y Growth Projections by End Users
  7.3. Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
     7.3.1. Hospital & Clinics
     7.3.2. Point of Care
     7.3.3. Diagnostic Centers
  7.4. Absolute $ Opportunity Assessment by End Users
  7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Human Papilloma Virus Testing Market Analysis and Forecast by Region
  8.1. Market Trends
  8.2. Introduction
     8.2.1. Basis Point Share (BPS) Analysis by Region
     8.2.2. Y-o-Y Growth Projections by Region
  8.3. Human Papilloma Virus Testing Market Size and Volume Forecast by Region
     8.3.1. North America
     8.3.2. Latin America
     8.3.3. Europe
     8.3.4. Asia Pacific
     8.3.5. Middle East and Africa (MEA)
  8.4. Absolute $ Opportunity Assessment by Region
  8.5. Market Attractiveness/Growth Potential Analysis by Region
  8.6. Global Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
9. North America Human Papilloma Virus Testing Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
  9.2. North America Human Papilloma Virus Testing Market Size and Volume Forecast by Country
     9.2.1. U.S.
     9.2.2. Canada
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. North America Human Papilloma Virus Testing Market Size and Volume Forecast by Types
     9.4.1. High-risk Human Papilloma Virus
     9.4.2. Low-risk Human Papilloma Virus
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. North America Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
     9.7.1. Monoclonal & Polyclonal Antibodies
     9.7.2. Immunoassays
     9.7.3. Chromosome Analysis
     9.7.4. Microarrays
     9.7.5. Molecular Diagnostics
     9.7.6. Flow Cytometry
     9.7.7. Artificial Intelligence
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. North America Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
     9.10.1. Hospital & Clinics
     9.10.2. Point of Care
     9.10.3. Diagnostic Centers
  9.11. Basis Point Share (BPS) Analysis by End Users
  9.12. Y-o-Y Growth Projections by End Users
  9.13. Market Attractiveness/Growth Potential Analysis
     9.13.1. By Country
     9.13.2. By Product Type
     9.13.3. By Application
  9.14. North America Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
10. Latin America Human Papilloma Virus Testing Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Latin America Average Pricing Analysis
  10.2. Latin America Human Papilloma Virus Testing Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
  10.4. Latin America Human Papilloma Virus Testing Market Size and Volume Forecast by Types
     10.4.1. High-risk Human Papilloma Virus
     10.4.2. Low-risk Human Papilloma Virus
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Latin America Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
     10.7.1. Monoclonal & Polyclonal Antibodies
     10.7.2. Immunoassays
     10.7.3. Chromosome Analysis
     10.7.4. Microarrays
     10.7.5. Molecular Diagnostics
     10.7.6. Flow Cytometry
     10.7.7. Artificial Intelligence
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Latin America Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
     10.10.1. Hospital & Clinics
     10.10.2. Point of Care
     10.10.3. Diagnostic Centers
  10.11. Basis Point Share (BPS) Analysis by End Users
  10.12. Y-o-Y Growth Projections by End Users
  10.13. Market Attractiveness/Growth Potential Analysis
     10.13.1. By Country
     10.13.2. By Product Type
     10.13.3. By Application
  10.14. Latin America Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
11. Europe Human Papilloma Virus Testing Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Europe Average Pricing Analysis
  11.2. Europe Human Papilloma Virus Testing Market Size and Volume Forecast by Country
     11.2.1. Germany
     11.2.2. France
     11.2.3. Italy
     11.2.4. U.K.
     11.2.5. Spain
     11.2.6. Russia
     11.2.7. Rest of Europe
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Europe Human Papilloma Virus Testing Market Size and Volume Forecast by Types
     11.4.1. High-risk Human Papilloma Virus
     11.4.2. Low-risk Human Papilloma Virus
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Europe Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
     11.7.1. Monoclonal & Polyclonal Antibodies
     11.7.2. Immunoassays
     11.7.3. Chromosome Analysis
     11.7.4. Microarrays
     11.7.5. Molecular Diagnostics
     11.7.6. Flow Cytometry
     11.7.7. Artificial Intelligence
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Europe Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
     11.10.1. Hospital & Clinics
     11.10.2. Point of Care
     11.10.3. Diagnostic Centers
  11.11. Basis Point Share (BPS) Analysis by End Users
  11.12. Y-o-Y Growth Projections by End Users
  11.13. Market Attractiveness/Growth Potential Analysis
     11.13.1. By Country
     11.13.2. By Product Type
     11.13.3. By Application
  11.14. Europe Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
12. Asia Pacific Human Papilloma Virus Testing Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Asia Pacific Average Pricing Analysis
  12.2. Asia Pacific Human Papilloma Virus Testing Market Size and Volume Forecast by Country
     12.2.1. China
     12.2.2. Japan
     12.2.3. South Korea
     12.2.4. India
     12.2.5. Australia
     12.2.6. Rest of Asia Pacific (APAC)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Asia Pacific Human Papilloma Virus Testing Market Size and Volume Forecast by Types
     12.4.1. High-risk Human Papilloma Virus
     12.4.2. Low-risk Human Papilloma Virus
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Asia Pacific Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
     12.7.1. Monoclonal & Polyclonal Antibodies
     12.7.2. Immunoassays
     12.7.3. Chromosome Analysis
     12.7.4. Microarrays
     12.7.5. Molecular Diagnostics
     12.7.6. Flow Cytometry
     12.7.7. Artificial Intelligence
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Asia Pacific Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
     12.10.1. Hospital & Clinics
     12.10.2. Point of Care
     12.10.3. Diagnostic Centers
  12.11. Basis Point Share (BPS) Analysis by End Users
  12.12. Y-o-Y Growth Projections by End Users
  12.13. Market Attractiveness/Growth Potential Analysis
     12.13.1. By Country
     12.13.2. By Product Type
     12.13.3. By Application
  12.14. Asia Pacific Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
13. Middle East & Africa Human Papilloma Virus Testing Market Analysis and Forecast
  13.1. Introduction
     13.1.1. Basis Point Share (BPS) Analysis by Country
     13.1.2. Y-o-Y Growth Projections by Country
     13.1.3. Middle East & Africa Average Pricing Analysis
  13.2. Middle East & Africa Human Papilloma Virus Testing Market Size and Volume Forecast by Country
     13.2.1. Saudi Arabia
     13.2.2. South Africa
     13.2.3. UAE
     13.2.4. Rest of Middle East & Africa (MEA)
  13.3. Absolute $ Opportunity Assessment by Country
  13.4. Middle East & Africa Human Papilloma Virus Testing Market Size and Volume Forecast by Types
     13.4.1. High-risk Human Papilloma Virus
     13.4.2. Low-risk Human Papilloma Virus
  13.5. Basis Point Share (BPS) Analysis by Types
  13.6. Y-o-Y Growth Projections by Types
  13.7. Middle East & Africa Human Papilloma Virus Testing Market Size and Volume Forecast by Applications
     13.7.1. Monoclonal & Polyclonal Antibodies
     13.7.2. Immunoassays
     13.7.3. Chromosome Analysis
     13.7.4. Microarrays
     13.7.5. Molecular Diagnostics
     13.7.6. Flow Cytometry
     13.7.7. Artificial Intelligence
  13.8. Basis Point Share (BPS) Analysis by Applications
  13.9. Y-o-Y Growth Projections by Applications
  13.10. Middle East & Africa Human Papilloma Virus Testing Market Size and Volume Forecast by End Users
     13.10.1. Hospital & Clinics
     13.10.2. Point of Care
     13.10.3. Diagnostic Centers
  13.11. Basis Point Share (BPS) Analysis by End Users
  13.12. Y-o-Y Growth Projections by End Users
  13.13. Market Attractiveness/Growth Potential Analysis
     13.13.1. By Country
     13.13.2. By Product Type
     13.13.3. By Application
  13.14. Middle East & Africa Human Papilloma Virus Testing Demand Share Forecast, 2019-2026
14. Competition Landscape
  14.1. Global Human Papilloma Virus Testing Market: Market Share Analysis
  14.2. Human Papilloma Virus Testing Distributors and Customers
  14.3. Human Papilloma Virus Testing Market: Competitive Dashboard
  14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     14.4.1. Biomedical Diagnostics
     14.4.2. Abbott
     14.4.3. BioMerieux
     14.4.4. CeMines, Inc.
     14.4.5. CanAG Diagnostics
     14.4.6. Siemens Healthcare
     14.4.7. Bio-Rad
     14.4.8. Epigenomics&a

The global human papillomavirus testing market has been segmented on the basis of

Types

  • High-risk Human Papilloma Virus
  • Low-risk Human Papilloma Virus

Applications

  • Monoclonal & Polyclonal Antibodies
  • Immunoassays
  • Chromosome Analysis
  • Microarrays
  • Molecular Diagnostics
  • Flow Cytometry
  • Artificial Intelligence
  • Biosensors
  • Microcomputers

End-users

  • Hospital & Clinics
  • Point of Care
  • Diagnostic Centers

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Biomedical Diagnostics
  • Abbott
  • bioMerieux
  • CeMines, Inc.
  • CanAG Diagnostics
  • Siemens Healthcare
  • Bio-Rad
  • Epigenomics
  • Fujirebio
  • Guided Therapeutics Inc.
  • Ipsogen
  • Gen-Probe
  • J&J Diagnostics
  • Hologic
  • Polartechnics
  • Qiagen
  • Roche
  • Radient Pharmaceuticals
  • OncoLab
  • Sequenom
  • Targeted Diagnostics & Therapeutics, Inc.

Some of the major players competing in the market are Biomedical Diagnostics; Abbott; bioMerieux; CeMines, Inc; CanAG Diagnostics; Siemens Healthcare; Bio-Rad; Epigenomics; Fujirebio; Guided Therapeutics Inc; Ipsogen; Gen-Probe; J&J Diagnostics; Hologic; Polartechnics; Qiagen; Roche; Radient Pharmaceuticals; OncoLab; Sequenom; and Targeted Diagnostics & Therapeutics, Inc.

These key players are mainly focusing on organic & inorganic strategies such as merger & acquisition, approvals for products and licenses, agreements, partnerships, collaborations, and regional expansions to sustain their revenue share in the market.

Human Papilloma Virus Testing Market by key players

Buy Report